



NSW
Therapeutic
Advisory
Group Inc.

Advancing
quality use
of medicines
in NSW

Fortnightly TAG Mail – resources list 24th October 2024

NSW TAG ACTIVITIES

Open: Expression of Interest for CATAG Project Officer

0.4FTE 8-9 months (starting Dec 2024/Jan 2025): please contact Lisa Pulver, CATAG National Coordinator for further information: catag.coordinator@outlook.com

2024 Meetings

NSW TAG General Meetings

- 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions

- Hospital adherence with the HRM Standard: Insulin COB 30/10/2024

Recently completed email discussions and surveys

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs

- Protocols for critical medicines in NSW public facilities

- Ongoing infliximab for immune therapy colitis

- Handling of medicines by perfusionists

Contact *Sasha Bennett* at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHP: Drug shortage stewardship: A novel solution for an old problem - [link](#)

AJHP: Hospital pharmacy emergency preparedness: Developing a strategy to respond to emergencies and major incidents - [link](#)

AP: Inhaler device selection for people with asthma or chronic obstructive pulmonary disease - [link](#)

AP Podcast: Achieving safe medication management during transitions of care from hospital - [link](#)

BMJ: How should I use AI at work? - [link](#)

BMJ: Health information for all: do large language models bridge or widen the digital divide? - [link](#)

EHJ: The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension - [link](#)

EHJ: The win ratio in cardiology trials: lessons learnt, new developments, and wise future use - [link](#)

EJHP: Investigating the capabilities of advanced large language models in generating patient instructions and patient educational material - [link](#)

IMJ: Environmental impact of pressurised metered dose inhalers versus dry powder and soft mist inhalers at a tertiary Melbourne hospital - [link](#)

IMJ: Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)

JAMA: - Testing and Evaluation of Health Care Applications of Large Language Models- [link](#)

JAMA: The Science of Biosimilars—Updating Interchangeability - [link](#)

JAMA Neur: Risk of Inflammatory CNS Diseases After TNFi Treatment for Autoimmune Diseases- [link](#)

Lancet: Driving down the cost of biologics: lessons from a nationalised health-care system - [link](#)

Lancet Haem: Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants - [link](#)

Lancet Neur: Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2)- [link](#)

MJA: Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)

MJA: Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context - [link](#)

Pharmacotherapy: Association between gastroprotective agents and AKI in patients receiving NSAIDs - [link](#)

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Helping patients to breathe easier with COPD standard - [link](#)
- New standard to tackle chronic lung disease missed in half of patients - [link](#)

NSW Health

- Public health warning: viral gastroenteritis on the rise - [link](#)

TGA

- Nitrosamine impurities acceptable intakes update - October 2024 - [link](#)
- TGA's decision to not register lecanemab (LEQEMBI) - [link](#)
- Our response to questions asked about the Essential Principles consultation - [link](#)
- Medical devices affected by the 3G network shutdown - [link](#)
- Addressing misinformation about excessive DNA in the mRNA vaccines - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Chronic Obstructive Pulmonary Disease Clinical Care Standard - [link](#)

Australian Government Department of Health

- Changes to vaping in Australia – Resources collection - [link](#)
- Biosimilar medicines subsidised on the Pharmaceutical Benefits Scheme – [fact sheet](#) – [bevacizumab](#) - [adalimumab](#)
- Medication Management Review Programs Dataset - [link](#)

Australian Institute for Health and Welfare (AIHW)

- National Core Maternity Indicators – [update](#) ; Mental health - [update](#)
- GEN Aged Care Data: Residential Aged Care Quality Indicators (quarterly update) - [link](#)
- Australia's Disability Strategy Outcomes Framework – [update](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- recommended for use within NHS Wales:
 - [Galsulfase](#) (Naglazyme®) for patients with mucopolysaccharidosis VI (N-acetylgalactosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome)
 - [Miglustat](#) for progressive neurological manifestations in adult and paediatric patients with Niemann-Pick type C disease
- Back-up antibiotic prescribing: Good practice guide - [link](#)
- Prescribing of branded generics in NHS Wales: Position statement - [link](#)

British Gynaecological Cancer Society

- Management of menopausal symptoms following treatment of gynaecological cancer - [link](#)

Canadian Agency for Drugs and Technologies in Health

- BRAF and MEK Inhibitors for Active or Symptomatic Melanoma Brain Metastasis - [link](#)

Canadian Pharmacists Association

- Break the Habit: Smoking cessation toolkit now available - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Department of Health and Social Care UK

- Proposed update to the statutory scheme to control the cost of branded health service medicines: Consultation response - [link](#)
- Updated National Patient Safety Alert: Discontinuation of Kay-Cee-L (potassium chloride 375mg/ml) (potassium chloride 5mmol/5ml) syrup - NatPSA/2024/011/DHSC – [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)
- Flecainide Acetate 25mg/5mL Oral solution for AV nodal reciprocating tachycardia, arrhythmias associated with Wolff- Parkinson- White Syndrome and similar conditions, paroxysmal atrial fibrillation, symptomatic sustained ventricular tachycardia, and non-sustained ventricular tachycardia
- Fruzaqla (fruquintinib) hard capsules - VEGF receptor inhibitor for adults with metastatic colorectal cancer previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, & irinotecan-based chemotherapy, ± anti-VEGF therapy ± anti-EGFR therapy if appropriate
- Wezenla (ustekinumab) for adults with moderate to severely active ulcerative colitis who have had inadequate response with/lost response to/ were intolerant to conventional therapy or a biologic or have contraindications to such therapies
- Licence extensions
- Aывakyt (avapritinib) - now covering treatment of adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm, and mast cell leukaemia
- Trodelvy (sacituzumab) - now covering treatment of adult patients with unresectable/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy, and ≥2 additional systemic therapies in the advanced setting

European Medicines Agency (EMA)

- European CHMP recommends:
- new indication for [sarilumab](#) (Kevzara) - polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper
- approval of [catumaxomab](#) (Korjony) for malignant ascites
- [concizumab](#) (Alhemo) for prevention of bleeding in patients with haemophilia A and B
- [Fluad](#) (surface antigen, inactivated, adjuvanted) influenza vaccine – prevention, 50 years and older
- [Flucelvax](#) (surface antigen, inactivated, prepared in cell cultures) influenza vaccine, prevention, adults and children
- indication extension for [ribociclib](#) (Kisqali) to include early breast cancer
- indication extension for [bulevirtide](#) (Hepcludex) & [eliglustat](#) (Cerdelga) to include paediatric patients
- [tislelizumab](#) indication extension to patients with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, and [with](#) previously untreated oesophageal squamous cell carcinoma (OSCC)
- indication extension for Yselyt ([linzaqolix choline](#)) to include endometriosis
- Buprenorphine Neuraxpharm ([buprenorphine](#)) for the substitution treatment of opioid dependence
- non-renewal of Duchenne muscular dystrophy med Translarna ([ataluren](#)) authorisation reconfirmed
- Masitinib AB Science ([masitinib](#)) refused for the treatment of amyotrophic lateral sclerosis

Food and Drug Administration (FDA) USA

- New Drug approvals
- inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer - [link](#)
- [Vyloy](#) (zolbetuximab-clzb) for gastric or gastroesophageal junction adenocarcinoma
- [Hympavzi](#) (marstacimab-hncq) to prevent or reduce bleeding episodes related to hemophilia A or B
- [Itovebi](#) (inavolisib) to treat locally advanced or metastatic breast cancer
- [Flyrcado](#) (flurpiridaz F 18) radioactive diagnostic drug to evaluate for myocardial ischemia & infarction
- [Zolbetuximab](#) for gastric/gastroesophageal Cancer
- [Vyalev](#) (AbbVie) novel levodopa-based regimen for Parkinson's

-- [Lumryz](#) once-nightly sodium oxybate for children with narcolepsy

Global Preparedness Monitoring Board

- The Changing Face of Pandemic Risk: 2024 Report - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- Approves Comirnaty KP.2 COVID-19 vaccine for adults - [link](#)
- Approves eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv) - [link](#)
- [Elafibranor](#) approved to treat adults with a rare liver disease known as primary biliary cholangitis
- [Donanemab](#) licensed for early stages of Alzheimer's disease in adult patients who have one or no copies of apolipoprotein E4 gene

NHS England

- Planning and implementing real-world artificial intelligence (AI) evaluations: lessons from the AI in Health and Care Award - [link](#)

National Institute for Health and Care Excellence (NICE) UK

- Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria ([TA1010](#))
- Belzutifan for treating tumours associated with von Hippel-Lindau disease ([TA1011](#))
- Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia ([TA1013](#))
- Updated Clinical Guideline: Acute kidney injury: prevention, detection and management [[NG148](#)]

National Institute for Health and Care Research (NIHR)

- Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT - [link](#)
- Strategies for older people living in care homes to prevent urinary tract infection: the StOP UTI realist synthesis - [link](#)
- NIHR commentaries: Stop smoking intervention in emergency departments helps people quit - [link](#)
- NIHR commentaries: Urinary problems in men - self-management advice is helpful - [link](#)

Neonatal & Paediatric Pharmacists Group

- Liquid Vitamin and Iron Supplements in Neonates and Children - [link](#)

Pharma

- Gilead announces plans to voluntarily withdraw US accelerated approval for sacituzumab govitecan (Trodelvy) for the treatment of locally advanced or metastatic urothelial cancer - [link](#)

Specialist Pharmacy Services NHS UK

- Quality assurance for aseptic services videos - [link](#)
- Understanding when a check adds value to medication processes - [link](#)
- Using mesalazine tablets appropriately - [link](#)

UK Health Security Agency

- Mpox vaccine PGD template (previously named smallpox vaccine PGD) - [link](#)
- Mpox (monkeypox): guidance – [update](#)

World Health Organisation (WHO)

- Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report - [link](#)
- Medical Product Alert N°4/2024: Falsified USP/EP PROPYLENE GLYCOL identified in the WHO Eastern Mediterranean Region - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Aquipta (atogepant) - hypersensitivity reactions added as common ADR, anaphylaxis as rare ADR
- Atomoxetine (various formulations), Dr Reddy's - information on the risk of serotonin syndrome when used concomitantly with other serotonergic medicines included, and to note severe cases of aggressive behaviour, hostility or emotional lability have been reported in paediatric patients
- Arava (leflunomide) - skin ulcers & impaired wound healing can occur. In the event of skin ulcers, if leflunomide is suspected, discontinuation should be considered. Also, based on individual assessment, it may be appropriate to interrupt treatment in the peri-surgical period
- Beovu (brolucizumab) - scleritis included as an uncommon ADR
- Buccolam (midazolam) - updated with information on use in adults, and note that it should be used with caution in elderly patients
- Bumetanide - may cause toxic epidermal necrolysis and Stevens Johnson syndrome
- Clomid (clomiphene) – contraindicated in patients with a history of significant, medically confirmed, vision disorders related to the use of the medicine has been removed from the SPC
- Copaxone (glatiramer) - anaphylactic reactions may occur shortly following administration of glatiramer, even months up to years after initiation of treatment. Fatalities have been reported. Some signs and symptoms of anaphylactic reactions may overlap with post-injection reactions
- Crestor (rosuvastatin) – genetic polymorphisms information updated. Genotypes of SLCO1B1 (OATP1B1) c.521CC & ABCG2 (BCRP) c.421AA associated with increased rosuvastatin exposure. For those with c.521CC or c.421AA genotype, half usual dose (& max 20mg daily) is recommended
- Drovelis (drospirenone, estetrol) - study which evaluated the effect of hepatic disease on the pharmacokinetics of estetrol. Results suggest the increase of plasma exposure in subjects with severe hepatic impairment vs normal hepatic function could be of clinical relevance
- Gadobutrol – 1.0mmol/ml - option of multidose use (single doses given to multiple sequential patients) added to the licence for 30mL vial & 65mL bottle products, when used with certified automatic injector systems (i.e., CE-marked) by a recognised Notified Body for multi-patient use
- Ibuleve (ibuprofen) 10% Gel - Interactions information updated to note that non-steroidal anti-inflammatory drugs may possibly enhance the effects of anticoagulants, although the chance of this occurring with a topically administered preparation is extremely remote
- Mounjaro (tirzepatide), Trulicity (dulaglutide), Wegovy (semaglutide) - pulmonary aspiration reported in patients on GLP-1 RAs undergoing general anaesthesia or deep sedation (GA/SD). Increased risk of residual gastric content due to delayed gastric emptying should thus be considered prior to performing procedures with GA/SD
- Myloxifin (oxycodone/naloxone) - concomitant administration of oxycodone with anticholinergics or medications with anticholinergic (AC) activity (e.g. tri-cyclic antidepressants, antihistamines, anti-psychotics, muscle relaxants, anti-Parkinson drugs) may result in increased AC adverse effects
- Nucala (mepolizumab) - Herpes Zoster/arthritis added as uncommon/common ADRs, respectively
- Octaplex (protein c, protein s, human coagulation factor II, human coagulation factor VII, human coagulation factor IX, human coagulation factor X) 500 IU and 1000 IU powder and solvent for solution for injection - dose is based on body weight up to, but not exceeding 100 kg. For patients weighing more than 100 kg, maximum single dose (IU of factor IX) should therefore not exceed 2500 IU for INR of 2 - < 4; 3500 IU for INR of 4 - 6 and 5000 IU for an INR of > 6
- Ponvory (ponesimod) - addition of wording on the potential risk of immune reconstitution inflammatory syndrome associated with progressive multifocal leukoencephalopathy, and its management
- Padcev (enfortumab vedotin) - use in combination with pembrolizumab first-line for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy
- Prograf (tacrolimus) – study data involving 289 pregnancies with first-trimester exposure included. Study results did not indicate a higher rate of major malformations but there was a higher rate of spontaneous abortion compared with other immunosuppressants
- Saxenda (liraglutide) - cutaneous amyloidosis added as an ADR of unknown frequency
- Spedra (avanafil) - Central Serous Chorioretinopathy (CSCR) included in the list of visual defects reported in connection with intake of PDE5 inhibitors

- Vargatef (nintedanib) - posterior reversible encephalopathy syndrome (PRES) reported post-marketing. If PRES is suspected, nintedanib treatment must be discontinued
- Wegovy (semaglutide) -cases of pulmonary aspiration reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation
- Willfact (von willebrand factor) 1000 IU Powder - updated to include all age groups. Information pertaining to use in the paediatric population added
- Risk minimisation materials
- Eisai Ltd: lecanemab ([Legembi](#)) - HP guide provides information about the risk & the management of amyloid related imaging abnormalities & intracerebral haemorrhage for patients with Alzheimer's disease receiving lecanemab. The patient alert card should be carried by patients at all times
- Janssen-Cilag Ltd: [Remicade](#) (infliximab) and Simponi (golimumab) Patient Reminder Cards - containing important safety information that patients need to be aware of before and during treatment
- PTC Therapeutics Ltd: [Upstaza](#) (Eladocagene exuparvovec) Materials include a pharmacy manual outlining how to receive and prepare the product for use, and a surgical guide to administration (it is infused directly into the putamen bilaterally in a single surgical session using stereotactic guidance)
- UCB Pharma Ltd: [Piasky](#) (crovalimab) Guide for healthcare professionals describes the potential increased risk of meningococcal infections, how to mitigate this risk (vaccination ± antibiotics), patient counselling, monitoring, provision of the Patient Card, & details of the Controlled Access Programme

Food and Drug Administration (FDA) USA

- 7 Things to Know About Drug Shortage Management - [link](#)

Health Canada

- Summary Safety Review: Sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin) - [link](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Calcium channel blockers and the possible risk of new-onset eczema - [update](#)

Monthly Index of Medical Specialities (MIMS) UK

- GLP-1 agonist Victoza (liraglutide) to be discontinued - [link](#)

TGA

- Shortage of Metalyse (tenecteplase) is resolved - [link](#)

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- Identifying disruptive papers in pharmacy literature that changed clinical practice: 1954-2014 - [link](#)
- Dual prostacyclin infusions: A case report of a patient symptom-driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension - [link](#)
- Severe hypersensitivity reactions to 2 immunotherapy agents in a patient with cutaneous squamous cell carcinoma - [link](#)
- Implementing a risk stratification protocol for patients with migraine in a health-system specialty pharmacy setting - [link](#)
- Drug shortage stewardship: A novel solution for an old problem - [link](#)
- Hospital pharmacy emergency preparedness: Developing a strategy to respond to emergencies and major incidents - [link](#)
- Physicochemical and microbiological stability of 40 mg/mL amiodarone hydrochloride oral suspension - [link](#)
- Reducing readmissions with pharmacist-integrated care in Medicare value-based programs - [link](#)

Annals of Internal Medicine

- Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug Administration - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

Arthritis & Rheumatology

- Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors for the Primary Prevention of Cardiovascular, Renal Events and Safety Outcomes in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation - [link](#)

Atherosclerosis

- Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials - [link](#)

Australian Prescriber

- Inhaler device selection for people with asthma or chronic obstructive pulmonary disease - [link](#)
- Managing medicine shortages – [link](#)
- Editorial: Reflections on community antimicrobial use in Australia - [link](#)
- Medicinal mishap: Immune checkpoint inhibitors and immune-related adverse events – [link](#)
- New drug: [Avacopan](#) for antineutrophil cytoplasmic antibody-associated vasculitis; [Clascoterone](#) for acne; [Fezolinetant](#) for moderate to severe vasomotor symptoms associated with menopause; [Prasterone](#) for vulvar and vaginal atrophy in postmenopausal women

British Journal of Clinical Pharmacology

- Drug-induced liver injury associated with pretomanid, bedaquiline, and linezolid: Insights from FAERS database analysis - [link](#)
- “Doctor, would it surprise you if there were prescribing errors in this patient's medication?” Identifying eligible patients for in-hospital pharmacotherapeutic stewardship: A matched case-control study - [link](#)
- Generating and translating evidence for safe and effective medication management in aged care homes - [link](#)

British Medical Journal (BMJ)

- Health information for all: do large language models bridge or widen the digital divide? - [link](#)
- Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial - [link](#)
- Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study - [link](#)
- Prioritising primary care patients with unexpected weight loss for cancer investigation: diagnostic accuracy study (update) - [link](#)
- Are covid-19 tests still working? - [link](#)
- Head To Head: Should recreational cannabis be legalised in the UK? - [link](#)
- Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study - [link](#)
- How should I use AI at work? - [link](#)

BMJ Open

- Metronomic chemotherapy for paediatric extracranial solid tumours: a systematic review and meta-analysis of randomised clinical trials - [link](#)
- Association between exposure to proton pump inhibitors and delirium: a descriptive and disproportionality analysis of VigiBase - [link](#)
- Real-world safety profile of zanubrutinib: a disproportionality analysis based on the FAERS database - [link](#)
- New cancer medicines in Europe 2010–2020: comparison of medicines with or without extensions of indications - [link](#)

British Journal of Psychiatry

- Association between dietary fat intake and the risk of Alzheimer's disease: Mendelian randomisation study - [link](#)

- Association of volatile substance, nitrous oxide and alkyl nitrate use with mental health in UK adolescents - [link](#)
- Pharmacological interventions for co-occurring psychopathology in people with borderline personality disorder: secondary analysis of the Cochrane systematic review with meta-analyses - [link](#)

Circulation

- Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association - [link](#)
- Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? - [link](#)

Cochrane

- Vitamin E for people with non-alcoholic fatty liver disease - [link](#)
- Blood pressure targets for hypertension in people with chronic renal disease - [link](#)
- Updated: Coronavirus (COVID-19): infection control and prevention measures - [link](#)

Diabetes Care

- Impact of Syringe and Needle Reuse on the Clinical Outcomes of Patients With Type 2 Diabetes: A 12-Week Randomized Clinical Trial - [link](#)
- Eighteen-Month Hybrid Closed-Loop Use in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Trial - [link](#)
- Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical Trial - [link](#)
- Regional Heterogeneity of the Results of Glucagon-Like Peptide 1 Receptor Agonist Trials in Type 2 Diabetes: A Reanalysis of Individual Participant Data - [link](#)
- The Supporting Emerging Adults With Diabetes (SEAD) Program: An Adult-Based Real-World Clinical Model That Improves Hospitalizations, Diabetes Technology Uptake, and Glycemic Outcomes in Underserved Young Adults With Type 1 Diabetes - [link](#)
- Risk of Infection in Older Adults With Type 2 Diabetes With Relaxed Glycemic Control - [link](#)

Drug and Therapeutics Bulletin

- DTB select: Bleeding risk with oral anticoagulant plus SSRI - [link](#)
- DTB select: Pharma funding of patient organisations - [link](#)
- DTB Select: Promising results from NHS type 2 diabetes low calorie diet programme - [link](#)

eClinicalMedicine

- Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update - [link](#)

European Heart Journal

- Great debate: pre-diabetes is not an evidence-based treatment target for cardiovascular risk reduction - [link](#)
- The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension - [link](#)
- The win ratio in cardiology trials: lessons learnt, new developments, and wise future use - [link](#)
- Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis - [link](#)
- Diet and risk of atrial fibrillation: a systematic review - [link](#)

European Journal of Hospital Pharmacy

- Stability of clozapine tablets repackaged in dose administration aids using repackaging machines - [link](#)
- Medication stability: from pharmacies to patients' homes—is consistent storage achievable? - [link](#)
- Investigating the capabilities of advanced large language models in generating patient instructions and patient educational material - [link](#)

- Case report: Neutropenia possibly caused by cefoperazone/sulbactam - [link](#)

Health Affairs

- Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review - [link](#)

Heart

- The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study - [link](#)

- Granulocyte colony-stimulating factor for stem cell mobilisation in acute myocardial infarction: a randomised controlled trial - [link](#)

- Nationwide burden of sudden cardiac death among patients with a psychiatric disorder - [link](#)

Internal Medicine Journal

- Pulmonary arterial hypertension: updates and perspective with newer therapies - [link](#)

- Development and validation of a predictive scoring system for hypoglycaemic agents for optimal control of blood glucose during glucocorticoid therapy - [link](#)

- Treatment outcomes of mild to moderate *Clostridioides difficile* infection in inflammatory bowel disease: an Australian experience - [link](#)

- Environmental impact of pressurised metered dose inhalers versus dry powder and soft mist inhalers at a tertiary Melbourne hospital - [link](#)

- Letter: Managing cancer-related pain in the setting of proven IgE-mediated opioid anaphylaxis - [link](#)

- Navigating high-cost medicines: summary of the Guiding Principles for the governance of high-cost medicines in Australian hospitals - [link](#)

International Journal of Clinical Pharmacy

- Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database - [link](#)

- The effect of clinical pharmacist-led pharmaceutical care services on medication adherence, clinical outcomes and quality of life in patients with stroke: a randomised controlled trial - [link](#)

JAMA

- Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review - [link](#)

- Testing and Evaluation of Health Care Applications of Large Language Models: A Systematic Review - [link](#)

- Community-Acquired Pneumonia: A Review - [link](#)

- The Science of Biosimilars—Updating Interchangeability - [link](#)

- Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems - [link](#)

- Payments by Drug and Medical Device Manufacturers to US Peer Reviewers of Major Medical Journals - [link](#)

- Patient Page: What Is Lupus? - [link](#)

- Antibiotics for Pediatric Acute Bacterial Sinusitis - [link](#)

- Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder - [link](#)

JAMA Cardiology

- Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis - [link](#)

JAMA Dermatology

- Drug survival of dupilumab, methotrexate, and cyclosporine a in children with atopic dermatitis - [link](#)

JAMA Internal Medicine

- GLP-1 Receptor Agonists and the path to sustainable obesity care - [link](#)

- Reducing wasteful spending on discarded lecanemab in the US Medicare Program - [link](#)

- High-risk medications in persons living with dementia: a randomized clinical trial - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

JAMA Neurology

- Endovascular vs Medical Management of Acute Basilar Artery Occlusion: A Secondary Analysis of a Randomized Clinical Trial - [link](#)
- Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases: A Systematic Review and Meta-Analysis - [link](#)
- Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis - [link](#)

Journal of the American College of Cardiology

- Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Evaluation of a weight-based process for real-time accurate confirmation of oral liquid controlled drug balances - [link](#)

Lancet

- The Lancet Commission on self-harm - [link](#)
- Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials - [link](#)
- Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial - [link](#)
- Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis - [link](#)
- Driving down the cost of biologics: lessons from a nationalised health-care system - [link](#)

Lancet Diabetes & Endocrinology

- Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013–17 in 63 countries worldwide: a population-based study - [link](#)

Lancet Haematology

- Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants - [link](#)

Lancet Infectious Diseases

- Adjunctive linezolid versus clindamycin for toxin inhibition in β -lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: a retrospective cohort study with target trial emulation - [link](#)
- Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study - [link](#)

Lancet Neurology

- Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial - [link](#)
- Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial - [link](#)

Lancet Oncology

- Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis - [link](#)

Lancet Psychiatry

- Global action on problematic usage of the internet: announcing a Lancet Psychiatry Commission - [link](#)

Lancet Regional Health (Europe)

- Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study - [link](#)

Lancet Respiratory Medicine

- Empirical antibiotic therapy for sepsis: save the anaerobic microbiota - [link](#)

Medical Journal of Australia

- Aligning legislation with clinical practice: off-label prescribing under the microscope - [link](#)
- Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context - [link](#)

Neurology

- Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis - [link](#)

New England Journal of Medicine

- Collagenase Injection versus Limited Fasciectomy for Dupuytren's Contracture - [link](#)
- Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy - [link](#)
- Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy - [link](#)
- Hairy-Cell Leukemia - [link](#)
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma - [link](#)
- Cryoglobulinemia — One Name for Two Diseases - [link](#)

Obesity

- Poor muscle health and cardiometabolic risks associated with antidepressant treatment - [link](#)

Pediatrics (American Academy of Pediatrics)

- Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis - [link](#)
- Clonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial – [link](#) - [commentary](#)

Pharmacotherapy

- Use of proton pump inhibitors and risk of severe COVID-19: A case–control study in United States Medicare beneficiaries - [link](#)
- Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population-based study - [link](#)
- Association between gastroprotective agents and acute kidney injury in patients receiving non-steroidal anti-inflammatory drugs: Analysis of a Japanese hospital-based database - [link](#)
- Impacts of age and BMI on vancomycin model choice in a Bayesian software: Lessons from a very large multi-site retrospective study - [link](#)

Thorax

- Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case–time–control study - [link](#)

CONSULTATIONS (new additions in bold)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Draft Medication Management at Transitions of Care Stewardship Framework - Closing 27 October 2024 - [link](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 174](#) – Achieving safe medication management during transitions of care from hospital

Clinical Communiqué

- [Episode #14](#): Thunderstorm asthma

MJA Podcasts

- [Episode 27](#) - Fertility treatment options and referrals

Purple Pen Podcast

[PPP167](#) - Meningococcal B

Specialist Pharmacy Service

- Pharmacy First podcast series (sinusitis, sore throat, otitis media, uncomplicated UTI, children) - [link](#)

UPCOMING EVENTS

AHHA

- Embedding patient-reported measures in practice – October 29, 2024, 12:30-13:00 AEDT - [register](#)
- AHHA Member Roundtable: Workforce Supply - November 20, 2024 12:00-13:30 AEDT - [register](#)

AHRQ

- Improving Hospital Handoffs Using AHRQ's Surveys on Patient Safety Culture® Hospital Survey – webinar - Oct. 30, 2024 13:00-14:00 ET - [register](#)

ASCEPT, APFP, APSA Joint Conference

Melbourne 1-4 December- [register](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- NMS 2024: Ageing well: safe medicines, better lives – Tuesday, 19 November 2024 10.00- 15.00 - [Register](#)

Institute for Healthcare Improvement-BMJ Group

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – [registration](#)

AdPha previously (Society of Hospital Pharmacists)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024